Photocure: New Hexvix®/Cysview® data to be presented during the 16th Annual SUO in Washington DC
Oslo, Norway, December 3, 2015: Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, today announces that new clinical data on Blue Light Cystoscopy with Hexvix/Cysview will be presented in three separate presentations during the Annual meeting of Society of Urologic Oncology (SUO) in Washington DC on December 3.
Blue Light Cystoscopy with Hexvix/Cysview is an advancement in detection and management of non-muscle invasive bladder cancer (NMIBC). The medical benefits and health economic benefits provided by Hexvix/Cysview have been well documented and are currently included in several national and international guidelines on bladder cancer. Hexvix/Cysview has been used in over 300,000 procedures to date, with consistent evidence that it improves detection and management of bladder cancer compared to White Light Cystoscopy alone.
Kjetil Hestdal, President & CEO comments: "We are pleased with the increased clinical use of Cysview in the US and the interest by renowned Urology institutions to evaluate and present new and important clinical data confirming some of the key medical benefits of the Hexvix/Cysview in management of bladder cancer patients "
The following clinical presentations on Hexvix/Cysview will be made at the SUO meeting on December 3:
- BLUE LIGHT CYSTOSCOCPY FOR DIAGNOSIS OF UROTHELIAL BLADDER CANCER RESULTS FROM PROSPECTIVE REGISTRY from the University of Southern California Institute of Urology and Norris Comprehensive Cancer Center, Los Angeles, CA
- BLUE LIGHT CYSTOSCOPY'S EFFECT ON MANAGEMENT OF BLADDER CANCER WHEN COMPARED TO TRADITIONAL WHITE-LIGHT CYSTOSCOPY from the UT Houston Medical School, Houston, TX; MD Anderson Cancer Center, Houston, TX
- EXAMINING THE EFFECT THAT PRIOR BLADDER MANIPULATION AND BCG TREATMENT HAVE ON FALSE POSITIVE RATES OF BLUE LIGHT CYSTOSCOPY BIOPSIES from UT Houston Medical School, Houston, TX; MD Anderson Cancer Center, Houston, TX
Access to the full meeting agenda can be found via the following link: http://bit.ly/1NkAmLq
Bladder cancer affects 577,000 people in the United States, with 74,690 newly diagnosed patients every year. Approximately 16,000 patients will die from the disease in 2015 mainly due to recurrence of the cancer.
*Cysview® is tradename in US and Canada, Hexvix® in Europe
For further information, please contact:
Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no
CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.no
About Photocure ASA
Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology® platform, Photocure develops and commercializes highly selective and effective solutions in disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions that can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com.
About Hexvix®/Cysview®
Hexvix®/Cysview® (hexaminolevulinate hydro-chloride) is an innovative breakthrough technology in the diagnosis and management of non-muscle-invasive bladder cancer. It is designed to selectively target malignant cells in the bladder and induce fluorescence during a cystoscopic procedure using a blue-light enabled cystoscope. Using Hexvix®/Cysview® as an adjunct to standard white-light cystoscopy enables the urologist to better detect and remove lesions, leading to a reduced risk of recurrence. Hexvix®/Cysview® is approved in Europe, Canada and the USA.